TD Cowen gave a positive view on biotechnology company Humacyte on Monday, raising his price target on the NASDAQ-listed stock (NASDAQ:HUMA) to $7.50, from the previous target of $6.00. The company maintained a Buy rating on the stock.
The price target adjustment comes as Humacyte is about to reach a major milestone with the FDA’s upcoming approval decision. The decision is expected to coincide with the August PDUFA date, the FDA’s deadline for review of new drug applications.
TD Cowen expressed confidence in Humacyte’s potential, particularly highlighting the commercial prospects of the company’s Human Acellular Vessel (HAV) product. The company believes that the product’s market entry is promising and that current estimates for the first full year of sales in 2025 are within reach.
The company’s progress towards the expected FDA decision is seen as a key factor in the positive analyst sentiment. The upcoming PDUFA date is a critical event that could catalyze further interest in the company’s stock, as it represents a critical step in bringing HAV to market.
Humacyte focuses on developing engineered human tissues that can be used in various medical procedures. The expected FDA approval is a crucial step for the company as it aims to commercialize its innovative tissue-based product with the potential to improve treatment options in vascular and other surgical procedures.
In other recent news, Humacyte, a biotechnology company specializing in bioengineered human tissue, has received approval of four new ICD-10-PCS codes from the U.S. Centers for Medicare & Medicaid Services for procedures involving the replacement of arteries with his human acellular vessels. This development is a key step towards submitting an application for additional payment for new technologies in 2024. The company also announced a reshuffle of the board of directors and the ratification of PricewaterhouseCoopers LLP as an independent auditor.
Humacyte reported a net loss of $31.9 million for the first quarter of 2024, but also secured $63 million in financing and ended the quarter with $115.5 million in cash and equivalents. The company’s biologics license application for the Humacyte Vascular Access Graft has been accepted by the FDA, which has granted priority review. These recent developments highlight Humacyte’s continued efforts to commercialize its flagship product.
Insights from InvestingPro
TD Cowen’s optimism towards Humacyte is further supported by the real-time data and analysis available on InvestingPro. With a market capitalization of $741.3 million, Humacyte is known to have more cash than debt, which is a solid indicator of the company’s financial health. Furthermore, the company’s strong performance is reflected in the significant return over the past year, with a total return of 118.94%. However, the company’s financials also show challenges, such as negative gross profit of $5.7 million in the trailing twelve months as of the first quarter of 2024, and analysts do not expect the company to be profitable this year .
InvestingPro’s tips highlight the high volatility of share price movements and the fact that the company trades at a price-to-book multiple of 32.1. These factors may be of interest to investors who feel comfortable with the company. These factors may be of interest to investors who are comfortable with high-risk, high-reward scenarios. Furthermore, Humacyte’s liquid assets exceed short-term obligations, providing some financial stability in the short term. For those considering investing in Humacyte, it’s worth noting that the company doesn’t pay a dividend, which could influence your investment decisions based on your income preferences.
For a more detailed analysis and more InvestingPro tips, visit InvestingPro. Subscribers can access 6 more recommendations to gain a complete understanding of Humacyte’s financial position and market potential. Use the coupon code PRONEWS24 to get an additional 10% discount on an annual or two-year subscription to Pro and Pro+, and to enhance your investment decisions with professional-level tools and insights.
This article was generated and translated with the support of artificial intelligence and reviewed by an editor. For further information, please see our T&Cs.
